FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT 9% Budget Boost for FDA, Biggest in Years
02/14/2019
 
 
TXT FDA ‘Least Burdensome’ Guidance ‘Could Be Worse’: Attorney
02/13/2019
 
 
TXT New Efforts Mulled to Modernize Dietary Supplement Regulation
02/11/2019
 
 
TXT CGMP Violations at Akorn Decatur Plant
02/13/2019
 
 
TXT Established Conditions Pilot Program
02/14/2019
 
 
TXT FDA Warns McKesson on Opioid Tampering
02/12/2019
 
 
TXT Device Makers to Get Nonbinding Feedback on Inspection Findings
02/15/2019
 
 
TXT Hill Seeks FDA Briefing on Blood Pressure Drug Recalls
02/13/2019
 
 
TXT Janssen Depression Drug Gains Joint Panel Backing
02/13/2019
 
 
TXT 2 Final Guidances on Regenerative Medicine
02/15/2019
 
 
TXT Latest Federal Register Notices
02/18/2019
 
 
TXT Product Approval Summaries
02/18/2019
 
 
TXT Since Our Last Issue ...
02/18/2019
 
 
TXT Medtronic Recall of Dual Chamber Implantable Pulse Generators
02/15/2019
 
 
TXT Vasisht Office of Women’s Health Deputy
02/14/2019
 
 
TXT QS Issues at Circulatory Technology
02/14/2019
 
 
TXT Issues Raised on Proposed IRB Consent Waiver
02/14/2019
 
 
TXT FDA OKs 1st Interoperable Insulin Pump
02/14/2019
 
 
TXT FDA Asked to Explain Dsuvia Approval
02/13/2019
 
 
TXT Immunomedics FDA-483 Has 13 Observations
02/13/2019
 
 
TXT Samson Pharmaceuticals Inspection Finds CGMP Issues
02/13/2019
 
 
TXT Draft CDER Consensus Standard Guidance
02/13/2019
 
 
TXT LC Medical Concepts Warned on Wound Kit Manufacturing
02/13/2019
 
 
TXT 4 Former FDAers Join Parexel
02/12/2019
 
 
TXT FDA Releases Lupin Limited FDA-483
02/12/2019
 
 
TXT FDA Appoints New Generic Drugs Director
02/12/2019
 
 
TXT Latest FDA Warning Letter
02/12/2019
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving